Corvus Pharmaceuticals Inc. CRVS
$11.81
▲ +2.84% 24H
About
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lead product candidate, soquelitinib, an oral small molecule designed to …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees37
TickerCRVS
Statistics
Market Cap$993.1M
Revenue (TTM)—
Net Income-$15.3M
Net Margin—
EPS$-0.53
P/E-64.21
P/S—
P/B4.05
EV/EBITDA-14.69
ROE-30.5%
Dividend Yield—
Price$11.81
Data: Twelve Data · Revenue = mcap / P/S